CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion
- PMID: 21984372
- DOI: 10.1007/s10585-011-9426-4
CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion
Abstract
CD24 is a glycosyl-phosphatidylinositol-anchored protein with mucin-type structure that resides exclusively in membrane microdomains. CD24 is often highly expressed in carcinomas and correlates with poor prognosis. Experimentally, the over-expression or depletion of CD24 alters cell proliferation, adhesion, and invasion in vitro and tumor growth in vivo. However, little is known about the mechanisms by which CD24 mediates these cellular effects. Here we have studied the mechanism of CD24-dependent cell invasion using transient CD24 knock-down or over-expression in human cancer cell lines. We show that CD24 depletion reduced tumor cell invasion and up-regulated expression of Tissue Factor Pathway Inhibitor 2 (TFPI-2), a potent inhibitor of extracellular matrix degradation that can block metastases formation and tumor cell invasion. Over-expression of CD24 in A125 cells resulted in reduced TFPI-2 expression and enhanced invasion. We provide evidence that the activity of c-Src is reduced upon CD24 knock-down. The silencing of c-Src, similar to CD24, was able to enhance TFPI-2 expression and reduce tumor cell invasion. An inverse expression of CD24 and TFPI-2 was observed by immunohistochemical analysis of primary breast cancers (N = 1,174). TFPI-2 expression was highest in CD24 negative samples and lowered with increasing CD24 expression. Patients with a CD24 low/TFPI-2 high phenotype showed significantly better survival compared to CD24 high/TFPI-2 low patients. Our results provide evidence that CD24 can regulate cell invasion via TFPI-2 and suggests a role of c-Src in this process.
Similar articles
-
CD24 controls Src/STAT3 activity in human tumors.Cell Mol Life Sci. 2012 Nov;69(22):3863-79. doi: 10.1007/s00018-012-1055-9. Epub 2012 Jul 4. Cell Mol Life Sci. 2012. PMID: 22760497 Free PMC article.
-
Contractile forces contribute to increased glycosylphosphatidylinositol-anchored receptor CD24-facilitated cancer cell invasion.J Biol Chem. 2011 Oct 7;286(40):34858-71. doi: 10.1074/jbc.M111.245183. Epub 2011 Aug 2. J Biol Chem. 2011. PMID: 21828044 Free PMC article.
-
CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion.Cell Mol Life Sci. 2012 Feb;69(3):435-48. doi: 10.1007/s00018-011-0756-9. Epub 2011 Jun 28. Cell Mol Life Sci. 2012. PMID: 21710320 Free PMC article.
-
The role of tissue factor pathway inhibitor-2 in cancer biology.Semin Thromb Hemost. 2007 Oct;33(7):653-9. doi: 10.1055/s-2007-991532. Semin Thromb Hemost. 2007. PMID: 18000791 Review.
-
From mechanism to therapy: the journey of CD24 in cancer.Front Immunol. 2024 May 31;15:1401528. doi: 10.3389/fimmu.2024.1401528. eCollection 2024. Front Immunol. 2024. PMID: 38881902 Free PMC article. Review.
Cited by
-
Surprising magic of CD24 beyond cancer.Front Immunol. 2024 Jan 19;14:1334922. doi: 10.3389/fimmu.2023.1334922. eCollection 2023. Front Immunol. 2024. PMID: 38313430 Free PMC article. Review.
-
Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.Cancer Res. 2017 Sep 15;77(18):4858-4867. doi: 10.1158/0008-5472.CAN-17-0367. Epub 2017 Jul 3. Cancer Res. 2017. PMID: 28674079 Free PMC article.
-
Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.Front Immunol. 2020 Jul 17;11:1324. doi: 10.3389/fimmu.2020.01324. eCollection 2020. Front Immunol. 2020. PMID: 32765491 Free PMC article. Review.
-
Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.CNS Neurosci Ther. 2021 Oct;27(10):1105-1117. doi: 10.1111/cns.13714. Epub 2021 Aug 6. CNS Neurosci Ther. 2021. PMID: 34363319 Free PMC article. Review.
-
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Cancers (Basel). 2017 Apr 26;9(5):40. doi: 10.3390/cancers9050040. Cancers (Basel). 2017. PMID: 28445439 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous